In this Webcast from a CCO symposium at ASH 2018, experts discuss ADCs, BiTE, and CAR T-cell therapies in the management of adults with Ph- ALL
Downloadable slides developed by expert faculty, Mary Beth Rios, RN, CCRP and Mary Alma Welch, PAC, on newer immunotherapies for ALL
NSCLC and MPM CME activity: Anne S. Tsao, MD, offers insights on challenging cases with variable symptoms, PD-L1 expression, and driver mutations.
Nursing resource for management of immunotherapy-related AEs in patients with ALL receiving blinatumomab, inotuzumab ozogamicin, or CAR T-cell therapy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.